Full index of posts »
Latest Followers
Latest Comments
-
on Why Nile May Succeed Where J&J Failed Jason, are you still in SPEX(D). It did 10 for ...
-
nasdaqczar on Why Nile May Succeed Where J&J Failed Jason you-re alright, $2 on spex? ok i was on t...
-
Jason Napodano on Why Nile May Succeed Where J&J Failed I think D-Tagatose for diabetes is dead in the ...
-
nasdaqczar on Why Nile May Succeed Where J&J Failed Hey Jason, what about spex .50c??? is a europe ...
Posts by Themes
Aastrom,
autologel,
Biotech,
CD-NP,
cell therapy,
Cenderitide,
CLI,
critical limb ischemia,
cytomedix,
DCM,
diabetes,
dont-tag-as-pro,
Elagolix,
elagolix,
endometriosis,
FV-100,
Gralise,
Heart Failure,
heart failure,
Intermezzo,
long-ideas,
Natrecor,
obesity,
PAD,
Probuphine,
Serada,
shingles,
stevia,
Synavive,
valacyclovir,
Zalicus
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
Jason Napodano doesn't have any Instablog posts